Kizilbash Sarah J, Evans Michael D, Chavers Blanche M
Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Clinical and Translational Science Institute, University of Minnesota, Minneapolis, MN.
Transplantation. 2022 Mar 1;106(3):575-583. doi: 10.1097/TP.0000000000003733.
Kidneys donated after circulatory death (DCD) are increasingly being used for transplantation in adults to alleviate organ shortage. Pediatric data on survival benefits of DCD transplantation compared with remaining on the waitlist for a kidney donated after brain death (DBD) offer are lacking.
We used Scientific Registry of Transplant Recipients to identify 285 pediatric (<18 y) DCD kidney transplants performed between 1987 and 2017. Propensity score matching was used to create a comparison group of 1132 DBD transplants. We used sequential Cox analysis to evaluate survival benefit of DCD transplantation versus remaining on the waitlist and Cox regression to evaluate patient and graft survival.
DCD transplantation was associated with a higher incidence of delayed graft function (adjusted odds ratio: 3.0; P < 0.001). The risks of graft failure (adjusted hazard ratio [aHR], 0.89; P = 0.46) and death (aHR, 1.2; P = 0.67) were similar between DCD and DBD recipients. We found a significant survival benefit of DCD transplantation compared with remaining on the waitlist awaiting a DBD kidney (aHR, 0.44; P = 0.03).
Despite a higher incidence of delayed graft function, long-term patient and graft survival are similar between pediatric DCD and DBD kidney transplant recipients. DCD transplantation in children is associated with a survival benefit, despite pediatric priority for organ allocation, compared with remaining on the waitlist.
循环死亡后捐赠的肾脏(DCD)越来越多地用于成人移植,以缓解器官短缺问题。目前缺乏关于DCD移植与继续等待脑死亡后捐赠的肾脏(DBD)相比在儿科患者中的生存获益数据。
我们利用移植受者科学登记处的数据,确定了1987年至2017年间进行的285例儿科(<18岁)DCD肾脏移植。采用倾向评分匹配法创建了一个由1132例DBD移植组成的对照组。我们使用序贯Cox分析评估DCD移植与继续等待名单相比的生存获益,并使用Cox回归评估患者和移植物的生存情况。
DCD移植与移植肾功能延迟发生率较高相关(调整后的优势比:3.0;P<0.001)。DCD和DBD受者的移植物失败风险(调整后的风险比[aHR],0.89;P=0.46)和死亡风险(aHR,1.2;P=0.67)相似。我们发现,与继续等待DBD肾脏的等待名单相比,DCD移植具有显著的生存获益(aHR,0.44;P=0.03)。
尽管移植肾功能延迟的发生率较高,但儿科DCD和DBD肾脏移植受者的长期患者和移植物生存率相似。与继续留在等待名单上相比,尽管儿科患者在器官分配上具有优先权,但儿童DCD移植仍具有生存获益。